1. Lesson Plan_Pre-clinical studies design 2. Pre-clinical studies - An overview - Ariel Angel 11.2022 3. Tech Transfer

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration:40mins https://www.bloodtransfusion.it/bt/article/view/332

https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-cancers-treatment-regimens/leukemia-treatment-regimens-acute-lymphoblastic-leukemia-all/ NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40mins Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central facility from cellular starting material containing...

Συμμετέχοντες: Σαγιαδινού Ε (QM Manager) Διαρκεια εκπαιδευσης: 8 ώρες Tύπος εκπαιδευσης: Eξ'αποστασεως Απονεμήθηκε πιστοποιητικο QMS Internal auditor

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation...

Administration and handling of cell product Management of Adverse Events Patient card

Find attached the article ''To Transplant or Not To Transplant in First Remission Acute Lymphoblastic Leukemia? Study group data give some answers, but not all.'' authored by Prof. Spyridonidis and published at American Society for Transplantation and Cellular Therapy

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (alloHCT) is recommended in first complete remission (CR1). However, in the...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 35 mins With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for...

Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou Duration: 40 mins

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou, E. Sagiadinou Duration: 40 mins Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Find attached the slides of PeerVoice seminar, presented by Prof Mohty  Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Dr Valera. Duration: 40 mins

Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Valera, Dr Tsokanas Duration: 40 mins These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas 

Find attached the presentation of Prof. Spyridonidis at 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) that was held on Berlin, 27-30 October 2022

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr. Tsokanas Duration: 20mins Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hemato- logic malignancies. Two CAR T products were recently approved in the United States...